Article
Endocrinology & Metabolism
Janet B. McGill, Daniel Weiss, Marshall Grant, Marisa C. Jones, David M. Kendall, Byron J. Hoogwerf
Summary: Comparing inhaled insulin with short-acting insulin analogues showed that inhaled insulin can improve post-meal glucose levels and reduce the risk of hypoglycemia.
JOURNAL OF DIABETES
(2021)
Article
Endocrinology & Metabolism
Ronald M. Goldenberg, Vanita R. Aroda, Liana K. Billings, A. Sia Louise Christiansen, Anders Meller Donatsky, Ehsan Parvaresh Rizi, Gracjan Podgorski, Katarina Raslova, David C. Klonoff, Richard M. Bergenstal
Summary: This study compared the use of insulin degludec and glargine U100 in patients with type 2 diabetes, showing that degludec performed better in terms of TIR and time in tight glycaemic range.
DIABETES OBESITY & METABOLISM
(2021)
Article
Medicine, General & Internal
Ravisha Bai, Kavita Batra, Charmaine Yap, Kenneth Izuora
Summary: This study aimed to compare diabetes-related outcomes between basal-bolus and premixed insulin regimens. The results showed no significant differences in glycemic control, hypoglycemia rate, or BMI between the two groups after one year of treatment. This suggests that premixed insulin is equally effective and safe as basal-bolus insulin.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES
(2023)
Article
Endocrinology & Metabolism
Huiying Wang, Yunting Zhou, Yuming Wang, Tingting Cai, Yun Hu, Ting Jing, Bo Ding, Xiaofei Su, Huiqin Li, Jianhua Ma
Summary: This study examined the glycaemic variability and safety of basal and premixed insulin in patients with type 2 diabetes. The results showed that compared to basal insulin, patients using premixed insulin had higher glycaemic variability, smaller time in range, and increased risk of hypoglycaemia.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
William H. Polonsky, Francesco Giorgino, Julio Rosenstock, Katherine Whitmire, Elisheva Lew, Mathieu Coudert, Agustina Alvarez, Charlie Nicholls, Rory J. McCrimmon
Summary: This study aimed to assess the efficacy and safety of iGlarLixi compared to BIAsp 30 in patients with T2D, and the impact on patient-reported outcomes. The results showed that iGlarLixi had greater improvements in TRIM-D scores and GTEE scores compared to BIAsp 30.
DIABETES OBESITY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Qi Pan, Yijun Li, Hailong Wan, Junfen Wang, Binhua Xu, Guoping Wang, Chengxia Jiang, Li Liang, Wei Feng, Jingcheng Liu, Ting Wang, Xia Zhang, Nan Cui, Yiming Mu, Lixin Guo
Summary: This study compared the efficacy and safety of basal insulin glargine plus oral antihyperglycemic drugs with premixed insulin aspart plus metformin in Chinese adults with type 2 diabetes after short-term intensive insulin therapy. The results showed that both treatment groups had similar reduction in HbA1c levels, but the group receiving basal insulin glargine had a lower risk of hypoglycemia.
DIABETES OBESITY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Anastasia-Stefania Alexopoulos, Andreas Andersen, Anders Meller Donatsky, Amoolya Gowda, John B. Buse
Summary: In both the DEVOTE and SWITCH 2 trials, insulin degludec 100 units/mL was shown to be superior to insulin glargine 100 units/mL in reducing rates of severe hypoglycemia in individuals with type 2 diabetes, regardless of diabetes duration. No significant interaction was observed between diabetes duration and treatment in the analysis of both trials.
DIABETES OBESITY & METABOLISM
(2021)
Article
Medicine, General & Internal
Harpreet S. Bajaj, Jens Aberle, Melanie Davies, Anders Meller Donatsky, Marie Frederiksen, Dilek G. Yavuz, Amoolya Gowda, Ildiko Lingvay, Bruce Bode
Summary: This study compared the effectiveness and safety of icodec titrated with a dosing guide app to once-daily basal insulin analogues in treating patients with type 2 diabetes. The results showed that icodec with app was more effective in reducing HbA1c levels, improving treatment satisfaction and compliance, with similar rates of hypoglycemia compared to OD analogues.
ANNALS OF INTERNAL MEDICINE
(2023)
Article
Endocrinology & Metabolism
Ying Peng, Peihong Xu, Juan Shi, Yifei Zhang, Shujie Wang, Qidong Zheng, Yufan Wang, Tingyu Ke, Li Li, Dong Zhao, Yuancheng Dai, Qijuan Dong, Bangqun Ji, Fengmei Xu, Weiqiong Gu, Weiqing Wang
Summary: This study found that once-daily basal insulin was more commonly prescribed and had similar glycemic control effects but less weight gain compared to twice-daily premixed insulin when used as initial therapy for patients with type 2 diabetes who had failed to achieve glycemic control with non-insulin medications.
JOURNAL OF DIABETES
(2022)
Article
Endocrinology & Metabolism
Rory J. McCrimmon, Alice Y. Y. Cheng, Gagik Galstyan, Khier Djaballah, Xuan Li, Mathieu Coudert, Juan P. Frias
Summary: This study compared the clinical effectiveness of iGlarLixi and BI + RAI regimens in patients with type 2 diabetes. The results showed that in real-world clinical practice, the two regimens had similar glycemic control, but iGlarLixi led to less weight gain.
DIABETES OBESITY & METABOLISM
(2023)
Review
Endocrinology & Metabolism
Paschalis Karakasis, Dimitrios Patoulias, Konstantinos Pamporis, Djordje S. Popovic, Panagiotis Stachteas, Konstantinos I. Bougioukas, Nikolaos Fragakis, Manfredi Rizzo
Summary: This study summarizes the evidence from recently published randomized controlled trials (RCTs) on the efficacy and safety of newly developed once-weekly basal insulin analogues in terms of glycaemic control. The results suggest that once-weekly insulins are more effective in reducing HbA1c and achieving a greater time in range compared to once-daily insulin analogues. The study concludes that once-weekly basal insulin analogues are at least equally effective and safe in glycaemic management as once-daily injections in people with type 2 diabetes mellitus (T2DM).
DIABETES OBESITY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Semah Tagougui, Laurent Legault, Elsa Heyman, Virginie Messier, Corinne Suppere, Kathryn J. Potter, Pascal Pigny, Serge Berthoin, Nadine Taleb, Remi Rabasa-Lhoret
Summary: This study aimed to investigate the effect of two key timings for basal insulin rate reduction on exercise-induced glucose changes and the association between circulating insulin concentrations and muscle vasoreactivity. The results showed that reducing basal insulin 40 minutes before exercise onset (T-40) or 90 minutes (T-90) attenuated the reduction in plasma glucose during exercise. However, T-90 delayed the occurrence of hypoglycemic episodes compared to T-40. It was also found that higher exercise-induced skeletal muscle vasodilatation was associated with a greater drop in plasma glucose.
DIABETES TECHNOLOGY & THERAPEUTICS
(2022)
Article
Endocrinology & Metabolism
Julie Maria Boggild Brosen, Rikke Mette Agesen, Peter Lommer Kristensen, Amra Ciric Alibegovic, Henrik Ullits Andersen, Henning Beck-Nielsen, Peter Gustenhoff, Troels Krarup Hansen, Christoffer Hedetoft, Tonny Jensen, Charlotte Ron Stolberg, Claus Bogh Juhl, Susanne Sogaard Lerche, Kirsten Norgaard, Hans-Henrik Parving, Lise Tarnow, Birger Thorsteinsson, Ulrik Pedersen-Bjergaard
Summary: This study compared the nocturnal glucose profiles in individuals with type 1 diabetes at risk for severe hypoglycemia, treated with insulin degludec and insulin glargine U100. The findings showed that treatment with insulin degludec resulted in lower glycemic variability and reduced risk of nocturnal hypoglycemia compared to insulin glargine U100.
DIABETES OBESITY & METABOLISM
(2023)
Article
Medicine, General & Internal
Wenying Yang, Juan Du, Minlu Zhang, Jing Hou, Xia Zhang, Nan Cui
Summary: This study aimed to identify the population of T2DM patients who are more likely to benefit from switching to basal insulin treatment. The results showed that patients with fasting C-peptide (FCP) levels greater than 1.2 nmol/L had a greater reduction in HbA1c and fasting plasma glucose (FPG) without increased risk of hypoglycemia compared to those with FCP levels less than or equal to 0.4 nmol/L.
CURRENT MEDICAL RESEARCH AND OPINION
(2022)
Article
Endocrinology & Metabolism
Philip D. Home, Rory J. McCrimmon, Julio Rosenstock, Matthias Bluher, Katrin Pegelow, Lydie Melas-Melt, Khier Djaballah, Francesco Giorgino
Summary: The aim of this study was to investigate the impact of baseline participant characteristics on the outcomes of the SoliMix study. The findings showed that the treatment effects of iGlarLixi were consistent across various baseline characteristics, supporting its use as an effective and well-tolerated treatment option for people with type 2 diabetes.
DIABETES OBESITY & METABOLISM
(2023)